Posted by Michael Wonder on 12 May 2018
PhRMA statement on President Trump’s drug pricing blueprint
11 May 2018 - Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement on President Donald Trump’s drug pricing blueprint:
“These far-reaching proposals could fundamentally change how patients access medicines and realign incentives across the entire prescription drug supply chain. While some of these proposals could help make medicines more affordable for patients, others would disrupt coverage and limit patients’ access to innovative treatments.
“The proposed changes to Medicare Part D could undermine the existing structure of the program that has successfully held down costs and provided seniors with access to comprehensive prescription drug coverage. We also must avoid changes to Medicare Part B that could raise costs for seniors and limit their access to lifesaving treatments.
